CYTK News Alert Cytokinetics Inc (CYTK) 8.01 01/01/2015 15:0
Post# of 64135
Posted On: 01/01/2015 4:04:12 PM
Cytokinetics Inc (CYTK) 8.01 $CYTK
Nasdaq stocks posting largest percentage increases
AP - Wed Dec 31, 6:59PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
RESN: 11.62 (+1.30), CYTK: 8.01 (+1.11), SIGM: 7.40 (+0.99), SIBC: 20.72 (+5.36), IDSA: 5.97 (+1.09), OCRX: 6.37 (+0.68), DJCO: 263.01 (+42.90)
Cytokinetics (CYTK) Stock Rises Today After Roth Capital Increases Price Target
at The Street - Wed Dec 31, 10:44AM CST
Shares of Cytokinetics (CYTK) were up in late morning trading Wednesday after Roth Capital increased its price target on the biotech company to $18 from $13.
CYTK: 8.01 (+1.11)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 8:15AM CST
CYTK: 8.01 (+1.11), NEON: 3.38 (+0.30), ARWR: 7.38 (-0.19), NRX: 13.35 (+8.70), PEIX: 10.33 (-0.38), BCLI: 4.76 (+0.88), MIG: 8.46 (+1.33), NDRM: 14.04 (-4.10)
Cytokinetics Shares Up 63.3% Since SmarTrend's Buy Recommendation (CYTK)
Comtex SmarTrend(R) - Tue Dec 30, 9:41AM CST
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on November 5th, 2014 at $4.23. In approximately 2 months, Cytokinetics has returned 63.33% as of today's recent price of $6.90.
CYTK: 8.01 (+1.11)
Kite Pharma Files IND for Non-Hodgkin Lymphoma Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 4:20PM CST
Kite Pharma, Inc. (KITE) submitted an investigational new drug application to the FDA for KTE-C19 for refractory aggressive non-Hodgkin lymphoma.
CYTK: 8.01 (+1.11), KITE: 57.67 (+1.73), MDCO: 27.67 (+0.02), AMGN: 159.29 (-1.34)
Cytokinetics continues Astellas-stoked up move
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 2:22PM CST
CYTK: 8.01 (+1.11)
Yamana Gold and Ocwen are big market movers
AP - Fri Dec 26, 3:24PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
CYTK: 8.01 (+1.11), TSLA: 222.41 (+0.18), SSO.TO: 5.83 (+0.10), ABX.TO: 12.52 (-0.08), YRI.TO: 4.69 (-0.02), ABX: 10.75 (-0.11), OCN: 15.10 (+0.38), SSRI: 5.01 (+0.07), AUY: 4.02 (-0.05)
Seeking Alpha's Biotech Weekly: AbbVie Slaps Gilead, Achillion's 'Nuc' Power, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Dec 26, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
MGNX: 35.07 (+0.95), CYTK: 8.01 (+1.11), JNJ: 104.57 (-0.79), ESRX: 84.67 (-1.08), ALNY: 97.00 (unch), GILD: 94.26 (-1.02), ACHN: 12.25 (-0.04), ABBV: 65.44 (-0.86), BMY: 59.03 (-0.36), ANIK: 40.74 (+0.58)
Strong On High Volume: Cytokinetics (CYTK)
at The Street - Fri Dec 26, 9:59AM CST
Trade-Ideas LLC identified Cytokinetics (CYTK) as a strong on high relative volume candidate
CYTK: 8.01 (+1.11)
Will Cytokinetics (CYTK) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 26, 8:50AM CST
Will Cytokinetics (CYTK) Continue to Surge Higher?
CYTK: 8.01 (+1.11)
Cytokinetics Rises After Extending Astellas Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 4:10PM CST
Cytokinetics (CYTK) shares jumped after announcing an amendment to its collaboration with Astellas.
CYTK: 8.01 (+1.11), AMGN: 159.29 (-1.34), AFFX: 9.87 (-0.12)
Myriad Genetics' Ovarian Cancer Test Wins FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 1:10PM CST
Myriad Genetics' (MYGN) BracAnalysis CDx has become the first and only FDA-approved test to be permitted for use with AstraZeneca's latest FDA-cleared ovarian cancer drug ??? LynParza.
CYTK: 8.01 (+1.11), MYGN: 34.06 (-0.77), AZN: 70.38 (-0.31), AFFX: 9.87 (-0.12)
Cytokinetics, Incorporated (CYTK) Rises: Stock Jumps 12.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 8:32AM CST
Cytokinetics, Incorporated (CYTK) was a big mover last session, as the company saw its shares rise more than 12% on the day.
CYTK: 8.01 (+1.11), AFFX: 9.87 (-0.12)
Will myRisk Cancer Test Work Wonders for Myriad Genetics? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 1:30PM CST
During the reported quarter,Myriad Genetics (MYGN) experienced heightened physician demand for the myRisk test.
CYTK: 8.01 (+1.11), MYGN: 34.06 (-0.77), ANIP: 56.39 (+2.03), AFFX: 9.87 (-0.12)
Walgreens Beats Q1 Earnings, Alliance Boots Deal Bears Fruit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 1:02PM CST
Walgreens reported an impressive first quarter fiscal 2015 with both the top and bottom line comfortably beating the Zacks Consensus Estimate.
CYTK: 8.01 (+1.11), ABC: 90.16 (-1.12), AFFX: 9.87 (-0.12), WAG: 76.05 (-0.49)
Uptrend Call Working As Cytokinetics Stock Rises 29.5% (CYTK)
Comtex SmarTrend(R) - Tue Dec 23, 9:34AM CST
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on November 5th, 2014 at $4.23. In approximately 2 months, Cytokinetics has returned 29.47% as of today's recent price of $5.47.
CYTK: 8.01 (+1.11)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 8:18AM CST
CYTK: 8.01 (+1.11), JRJC: 5.32 (-0.24), RDN: 16.72 (-0.11), CHK: 19.57 (-0.07), VNDA: 14.32 (-0.19), DRL: 3.95 (-0.09), ARIA: 6.87 (+0.05), ICLD: 2.92 (-0.02), NQ: 3.91 (-0.10)
Nasdaq stocks posting largest percentage increases
AP - Wed Dec 31, 6:59PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
RESN: 11.62 (+1.30), CYTK: 8.01 (+1.11), SIGM: 7.40 (+0.99), SIBC: 20.72 (+5.36), IDSA: 5.97 (+1.09), OCRX: 6.37 (+0.68), DJCO: 263.01 (+42.90)
Cytokinetics (CYTK) Stock Rises Today After Roth Capital Increases Price Target
at The Street - Wed Dec 31, 10:44AM CST
Shares of Cytokinetics (CYTK) were up in late morning trading Wednesday after Roth Capital increased its price target on the biotech company to $18 from $13.
CYTK: 8.01 (+1.11)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 8:15AM CST
CYTK: 8.01 (+1.11), NEON: 3.38 (+0.30), ARWR: 7.38 (-0.19), NRX: 13.35 (+8.70), PEIX: 10.33 (-0.38), BCLI: 4.76 (+0.88), MIG: 8.46 (+1.33), NDRM: 14.04 (-4.10)
Cytokinetics Shares Up 63.3% Since SmarTrend's Buy Recommendation (CYTK)
Comtex SmarTrend(R) - Tue Dec 30, 9:41AM CST
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on November 5th, 2014 at $4.23. In approximately 2 months, Cytokinetics has returned 63.33% as of today's recent price of $6.90.
CYTK: 8.01 (+1.11)
Kite Pharma Files IND for Non-Hodgkin Lymphoma Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 4:20PM CST
Kite Pharma, Inc. (KITE) submitted an investigational new drug application to the FDA for KTE-C19 for refractory aggressive non-Hodgkin lymphoma.
CYTK: 8.01 (+1.11), KITE: 57.67 (+1.73), MDCO: 27.67 (+0.02), AMGN: 159.29 (-1.34)
Cytokinetics continues Astellas-stoked up move
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 2:22PM CST
CYTK: 8.01 (+1.11)
Yamana Gold and Ocwen are big market movers
AP - Fri Dec 26, 3:24PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
CYTK: 8.01 (+1.11), TSLA: 222.41 (+0.18), SSO.TO: 5.83 (+0.10), ABX.TO: 12.52 (-0.08), YRI.TO: 4.69 (-0.02), ABX: 10.75 (-0.11), OCN: 15.10 (+0.38), SSRI: 5.01 (+0.07), AUY: 4.02 (-0.05)
Seeking Alpha's Biotech Weekly: AbbVie Slaps Gilead, Achillion's 'Nuc' Power, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Dec 26, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
MGNX: 35.07 (+0.95), CYTK: 8.01 (+1.11), JNJ: 104.57 (-0.79), ESRX: 84.67 (-1.08), ALNY: 97.00 (unch), GILD: 94.26 (-1.02), ACHN: 12.25 (-0.04), ABBV: 65.44 (-0.86), BMY: 59.03 (-0.36), ANIK: 40.74 (+0.58)
Strong On High Volume: Cytokinetics (CYTK)
at The Street - Fri Dec 26, 9:59AM CST
Trade-Ideas LLC identified Cytokinetics (CYTK) as a strong on high relative volume candidate
CYTK: 8.01 (+1.11)
Will Cytokinetics (CYTK) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 26, 8:50AM CST
Will Cytokinetics (CYTK) Continue to Surge Higher?
CYTK: 8.01 (+1.11)
Cytokinetics Rises After Extending Astellas Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 4:10PM CST
Cytokinetics (CYTK) shares jumped after announcing an amendment to its collaboration with Astellas.
CYTK: 8.01 (+1.11), AMGN: 159.29 (-1.34), AFFX: 9.87 (-0.12)
Myriad Genetics' Ovarian Cancer Test Wins FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 1:10PM CST
Myriad Genetics' (MYGN) BracAnalysis CDx has become the first and only FDA-approved test to be permitted for use with AstraZeneca's latest FDA-cleared ovarian cancer drug ??? LynParza.
CYTK: 8.01 (+1.11), MYGN: 34.06 (-0.77), AZN: 70.38 (-0.31), AFFX: 9.87 (-0.12)
Cytokinetics, Incorporated (CYTK) Rises: Stock Jumps 12.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 8:32AM CST
Cytokinetics, Incorporated (CYTK) was a big mover last session, as the company saw its shares rise more than 12% on the day.
CYTK: 8.01 (+1.11), AFFX: 9.87 (-0.12)
Will myRisk Cancer Test Work Wonders for Myriad Genetics? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 1:30PM CST
During the reported quarter,Myriad Genetics (MYGN) experienced heightened physician demand for the myRisk test.
CYTK: 8.01 (+1.11), MYGN: 34.06 (-0.77), ANIP: 56.39 (+2.03), AFFX: 9.87 (-0.12)
Walgreens Beats Q1 Earnings, Alliance Boots Deal Bears Fruit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 1:02PM CST
Walgreens reported an impressive first quarter fiscal 2015 with both the top and bottom line comfortably beating the Zacks Consensus Estimate.
CYTK: 8.01 (+1.11), ABC: 90.16 (-1.12), AFFX: 9.87 (-0.12), WAG: 76.05 (-0.49)
Uptrend Call Working As Cytokinetics Stock Rises 29.5% (CYTK)
Comtex SmarTrend(R) - Tue Dec 23, 9:34AM CST
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on November 5th, 2014 at $4.23. In approximately 2 months, Cytokinetics has returned 29.47% as of today's recent price of $5.47.
CYTK: 8.01 (+1.11)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 8:18AM CST
CYTK: 8.01 (+1.11), JRJC: 5.32 (-0.24), RDN: 16.72 (-0.11), CHK: 19.57 (-0.07), VNDA: 14.32 (-0.19), DRL: 3.95 (-0.09), ARIA: 6.87 (+0.05), ICLD: 2.92 (-0.02), NQ: 3.91 (-0.10)
(0)
(0)Scroll down for more posts ▼